Revenue (Annual)

Revenue: The sum of all revenue fields included for a company's operating activities.

Syndax Pharmaceuticals, Inc. (SNDX) had Revenue of $23.68M for the most recently reported fiscal year, ending 2024-12-31.

Quarterly Annual

Figures for fiscal year ending 2024-12-31

Income Statement Financials
Revenue	$23.68M
Net Income	$-318.76M
Cost of Goods Sold	$0.83M
Gross Profit	$22.85M
Operating Expenses	$363.35M
Operating Income	$-339.67M
Non-Operating Income/Expense	$20.91M
Pre-Tax Income	$-318.76M
Normalized Pre-Tax Income	$-318.76M
Income after Taxes	$-318.76M
Income from Continuous Operations	$-318.76M
Consolidated Net Income/Loss	$-318.76M
Normalized Income after Taxes	$-318.76M
EBIT	$-339.67M
EBITDA	$-353.10M
Weighted-Average Shares Outstanding (Basic)	85.62M
Weighted-Average Shares Outstanding (Diluted)	85.62M
Earnings per Share (EPS) (Basic)	$-3.72
Earnings per Share (EPS) (Diluted)	$-3.72
Balance Sheet Financials
Current Assets	$603.06M
Property, Plant, and Equipment	--
Long-Term Assets	$121.76M
Total Assets	$724.82M
Current Liabilities	$103.55M
Long-Term Debt	$331.56M
Long-Term Liabilities	$333.14M
Total Liabilities	$436.69M
Common Equity	$288.12M
Tangible Shareholders Equity	$288.12M
Shareholders Equity	$288.12M
Common Shares Outstanding	85.69M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-274.90M
Cash Flow from Investing Activities	$-219.78M
Cash Flow from Financial Activities	$353.37M
Beginning Cash	$295.61M
End Cash	$154.30M
Increase/Decrease in Cash	$-141.31M
Stock-Based Compensation	$43.03M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	5.82
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.54
Debt to Equity Ratio	1.19
Gross Margin	96.51%
Operating Margin	-1434.43%
EBIT Margin	-1434.43%
EBITDA Margin	-1491.14%
Pre-Tax Profit Margin	-1346.11%
Profit Margin	-1346.11%
Free Cash Flow	$-274.90M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.03
Inventory Turnover	2.26
Receiveable Turnover	2.11
Days Sales in Receivables	173.21
Return on Equity	-110.63%
Return on Tangible Equity	-110.63%
Return on Assets	-43.98%
Return on Investments	-51.44%
Book Value Per Share	$3.36
Free Cash Flow per Share	$-3.21
Operating Cash Flow per Share	$-3.21

Data from Zacks Investment Research, Inc.